Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 108 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: sodium divalproex Clear all
Terminated Phase 1 Interventional

Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma

NCT02648633
View directory record Official record
Conditions
Glioblastoma
Interventions
Stereotactic Radiosurgery, Nivolumab, Valproate
Radiation · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 22, 2026, 1:52 AM EDT
Not listed Phase 4 Interventional

Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study)

NCT00794625
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Valproate, Risperidone, Placebo, Stimulant medication, Behavioral family counseling
Drug · Behavioral
Lead sponsor
Joseph Blader
NIH
Eligibility
6 Years to 12 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Glen Oaks, New York • Stony Brook, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Oct 22, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

Divalproex Sodium vs. Placebo in Childhood/Adolescent Autism

NCT00211757
View directory record Official record
Conditions
Autism
Interventions
Divalproex sodium, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
5 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Oct 22, 2026, 1:52 AM EDT
Terminated Phase 3 Interventional

A Study of the Safety and Efficacy of Depakote Sprinkle Capsules in the Treatment of Partial Seizures in Children

NCT00067431
View directory record Official record
Conditions
Partial Seizure Disorder
Interventions
Divalproex Sodium (Depakote® Sprinkle Capsules)
Drug
Lead sponsor
Abbott
Industry
Eligibility
3 Years to 10 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
7
States / cities
Tampa, Florida • Cleveland, Ohio • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2006 · Synced Oct 22, 2026, 1:52 AM EDT
Suspended Phase 1Phase 2 Interventional

Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

NCT03919292
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
Neratinib, Divalproex Sodium
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2031
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 22, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Divalproex Sodium Delayed-Release Tablets Under Non-Fasting Conditions

NCT00834990
View directory record Official record
Conditions
Healthy
Interventions
divalproex sodium, Depakote®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2009 · Synced Oct 22, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents

NCT00057681
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium carbonate, Valproate, Risperidone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Years to 15 Years
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 22, 2026, 1:52 AM EDT
Completed Phase 4 Interventional Results available

Effect of Valproic Acid Concentration on Photic Response

NCT00609245
View directory record Official record
Conditions
Photosensitive Epilepsy
Interventions
Valproic Acid, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
15 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Chesterfield, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 22, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite

NCT04902105
View directory record Official record
Conditions
Drug Interaction
Interventions
ecopipam HCL, Mefenamic acid, Divalproex Sodium ER
Drug
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 22, 2026, 1:52 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Valproic AcId for Traumatic BRAin INjury Trial

NCT07166393
View directory record Official record
Conditions
Moderate Traumatic Brain Injury (TBI), Severe Traumatic Brain Injury
Interventions
Valproic Acid (VPA), Standard of care treatment + normal saline
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
8
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 22, 2026, 1:52 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder

NCT00667745
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate, Optimized Treatment (OPT)
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 80 Years
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Stanford, California • Boston, Massachusetts • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 22, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression

NCT00194116
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Divalproex Sodium ER, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
16 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 22, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex

NCT01358357
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Lurasidone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
965 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
26
States / cities
Dothan, Alabama • Glendale, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2016 · Synced Oct 22, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Results available

Characterization of Epilepsy Patients BEEP 2b

NCT02707965
View directory record Official record
Conditions
Epilepsy
Interventions
Oxcarbazepine (brand name vs generic drugs), Divalproex Sodium (brand name vs generic drugs), Carbamazepine (brand name vs generic drugs), Lamotrigine (brand name vs generic drugs), levetiracetam (brand name vs generic drugs), Topiramate (brand name vs generic drugs), Zonisamide (brand name vs generic drugs), Phenytoin sodium (brand name vs generic drugs)
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 76 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 22, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder

NCT00194129
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium, Divalproex, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
16 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 22, 2026, 1:52 AM EDT
Completed Phase 3 Interventional

Divalproex Sodium (Depakote) for Explosive Tempers in Adolescents and Adults

NCT00218114
View directory record Official record
Conditions
Attention Deficit and Disruptive Behavior Disorders, Marijuana Abuse
Interventions
Divalproex Sodium, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
12 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 22, 2026, 1:52 AM EDT
Completed Phase 2 Interventional

Effects of Lithium and Divalproex'on Brain-Derived Neurotrophic Factor in Huntington's Disease

NCT00095355
View directory record Official record
Conditions
Huntington's Disease
Interventions
Lithium, Divalproex
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 1:52 AM EDT
Completed Phase 2 Interventional

Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia

NCT00073164
View directory record Official record
Conditions
Schizophrenia
Interventions
Divalproex Sodium Extended-Release Tablets, Olanzapine, Risperidone
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
35
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2006 · Synced Oct 22, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Combination Therapy in Dual Diagnosis Bipolar Rapid Cycling

NCT00221975
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Divalproex, Lamotrigine, Lithium
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
16 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 22, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma

NCT01817751
View directory record Official record
Conditions
Glioblastoma, Recurrent Adult Brain Neoplasm, Malignant Glioma, WHO Grade III Glioma
Interventions
sorafenib tosylate, valproic acid, sildenafil citrate
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 22, 2026, 1:52 AM EDT
Terminated Phase 4 Interventional

Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness

NCT00071253
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Divalproex Sodium (Delayed-Release Tablets), Divalproex Sodium (Extended-Release Tablets), Olanzapine
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
15
States / cities
Anaheim, California • Chula Vista, California • Fort Meyers, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2006 · Synced Oct 22, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma

NCT00879437
View directory record Official record
Conditions
Glial Cell Tumors, Malignant Gliomas, Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliomatosis Cerebri, Gliosarcoma, Brainstem Glioma, Diffuse Intrinsic Pontine Glioma
Interventions
Valproic acid, Bevacizumab, Radiation therapy
Drug · Radiation
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Years to 21 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
6
States / cities
Oklahoma City, Oklahoma • Dallas, Texas • Fort Worth, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 22, 2026, 1:52 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Light at Night Study

NCT04251234
View directory record Official record
Conditions
Bipolar Disorder, Light Sensitivity
Interventions
Light intensity, ~30 lux, Baseline light intensity, <1 lux
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 45 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 22, 2026, 1:52 AM EDT
Completed Phase 2Phase 3 Interventional

Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms

NCT00202514
View directory record Official record
Conditions
Alcoholism, Alcohol Related Disorders, Mood Disorders
Interventions
divalproex sodium extended release
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 8, 2009 · Synced Oct 22, 2026, 1:52 AM EDT